Vericel Corp (VCEL) Company Profile & Statistics

Vericel Corp
VCEL
(Nasdaq - US)
Closed
56.68
-0.58 (-1.01%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
57.50
High
58.46
Low
56.20

About Vericel Corp

CEO

Dominick C. Colangelo

Headquarters

64 sidney street

cambridge, ma 02139, united states

Auditor

PricewaterhouseCoopers LLP

Employees

314

Share Holders

170

Website

www.vcel.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.

Vericel Corp Statistics

Valuation Measures

Market Capitalization ²	2.80B
Enterprise Value	2.73B
Enterprise Value/EBITDA (ttm)	760.99
Price to Earnings Ratio (ttm)	930.50
Price to Book (mrq)	10.63
Price to Sales (ttm)	12.15
Price to Cash (ytd)	3.17K

Profitability

Gross Margin (ttm)	71.25%
Operating Margin (ttm)	1.56%
Profit Margin (ttm)	0.50%
Return on Equity (ttm)	1.48%
Return on Invested Capital (ttm)	1.82%
Return on Assets (ttm)	0.96%

Income Statement

Revenue (ttm)	226.84M
Revenue Per Share (ttm)	4.60
Gross Profit (ttm)	162.11M
EBITDA (ttm)³	3.58M
Net Income Avi to Common (ttm)	3.55M
Diluted EPS (ttm)	0.06

Share Statistics

Beta (5Y Monthly)	1.66
52-Week Change	54.57%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	49.36M
Dividend Yield	0.00%
Float ⁴	46.79M
% Held by Insiders	5.20%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	118.40M
Total Cash Per Share (mrq)	2.40
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	4.61%
Quick Ratio (mrq)	4.23%
Book Value Per Share (mrq)	5.23

Cash Flow

Operating Cash Flow Per Share (ytd)	0.73
Free Cash Flow (ytd)	-14.27M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Vericel Corp

Trade With A Regulated Broker